Dysregulation of Innate Immune Responses by Borrelia burgdorferi:A Role for IL-10

伯氏疏螺旋体引起的先天免疫反应失调：IL-10 的作用

• 批准号: 7527261
• 负责人: RONALD MARK WOOTEN
• 金额: $ 37.08万
• 依托单位: UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7527261
• 关键词: Accounting; Acute; Address; Affect; Animals; Antibodies; Antibody Formation; Automobile Driving; Back; Bacteria; Bacterial Infections; Biological; Biological Assay; Biological Response Modifiers; Blocking Antibodies; Bone Marrow; Borrelia burgdorferi; Cell physiology; Cells; Chimera organism; Chronic; Confocal Microscopy; Data; Dendritic Cells; Deposition; Depressed mood; Development; Disease; Environment; Enzyme-Linked Immunosorbent Assay; Exhibits; Failure; Genetic; Goals; Green Fluorescent Proteins; Immune; Immune response; In Vitro; Indigenous; Infection; Infectious Agent; Interleukin-10; Knock-out; Lead; Leukocytes; Lipoproteins; Lyme Disease; Mediating; Medical; Modeling; Mus; Mutate; Nature; Numbers; Order Spirochaetales; Pathway interactions; Patients; Phagocytosis; Process; Production; Productivity; Public Health; Publishing; Relative (related person); Research; Role; Signal Pathway; Site; Skin; Skin Tissue; Source; Staging; Staining method; Stains; Surface Antigens; T-Lymphocyte; TLR2 gene; Testing; Ticks; Tigers; Time; Tissues; Toll-Like Receptor 2; Transgenic Mice; Transgenic Organisms; United States; Viral; Virulence; Wild Type Mouse; base; cell type; cellular targeting; cytokine; day; in vivo; interleukin-10 receptor; killings; macrophage; novel; pathogen; prevent; research study; response; trafficking; vector

DESCRIPTION (provided by applicant): Most people infected with Borrelia burgdorferi (Bb) will develop Lyme disease, which accounts for >90% of all vector-borne illnesses in the United States, and e $1-2 billion each year in direct medical expenses and lost productivity. This infection elicits potent innate and adaptive immune responses that often fail to clear the bacteria, leading to persistent infection and disease in targeted tissues. Early recognition of Bb lipoproteins through Toll-like receptor 2 on innate immune cells appears to be crucial for bacterial clearance from host tissues, however we currently have no clear understanding of the particular innate responses that are critical for preventing Lyme disease. Our previous studies revealed that IL-10-deficient mice (IL-10-/-) control Bb levels in host tissues significantly better than wild type (WT) mice, thus making IL-10 the only cytokine shown to significantly affect Bb clearance. Our preliminary data further indicate that 1) viable (but not killed) Bb elicit high IL-10 levels from murine macrophages (MXs) and dendritic cells (DCs), 2) that the secreted levels of IL-10 can significantly inhibit subsequent activation of resident MXs, 3) that significant IL-10 levels are detected in mouse skin within 24h of infection, and 4) that IL-10-/- mice do not exhibit these suppressive effects, leading to enhanced MX activity and immune clearance. We hypothesize that the IL-10 elaborated in response to Bb infection, suppresses host innate immune responses that are crucial for efficient Bb clearance from host tissues, and that MX and DC functions are central to this dysregulated host response. The overall goals of this proposal are: 1) to identify the cell types that initially detect and respond to Bb in murine tissues, 2) to determine which cell types are responsible for producing IL-10 during the course of infection, and 3) to delineate which immune cell types are adversely affected by Bb-elicited IL-10 and which immune mechanisms are dysregulated. To approach these goals, Aim 1 will compare IL-10 effects on the abilities of MXs and DCs to ingest, internally traffic, and mediate killing of Bb in vitro, including the expression of activation/maturation markers. Aim 2 will utilize a number of genetically mutated mouse lines to delineate the relative importance of hemopoietic and nonhemopoietic cells, as well as MXs, DCs, and T cells to both produce IL-10 and/or respond to IL-10 during Bb infection in vivo. Aim 3 will rigorously test whether administration of IL-10 receptor-blocking antibodies could be used as a curative therapy for mice infected with Bb. These studies should clarify specific host immune mechanisms that are suppressed during the development of Lyme disease, leading to the development of novel treatments. PUBLIC HEALTH RELEVANCE Infection with B. burgdorferi causes host tissues to significantly increase IL-10 production, which suppresses the host immune responses and hinders their ability to clear this infection, leading to the development of Lyme disease. IL-10 is the only cytokine that is currently known to significantly affect the development of Lyme disease and represents an important clue into the immune evasion mechanism of this pathogen. These studies intend to identify the host cells that produce IL-10, as well as the immune cells that are dysregulated by IL-10, thus identifying mechanisms that could be targeted to treat Lyme disease patients.

描述（由申请人提供）：大多数感染伯氏疏螺旋体（Bb）的人会患上莱姆病，莱姆病占美国所有病媒传播疾病的90%，每年造成10 - 20亿美元的直接医疗费用和生产力损失。这种感染引起强大的先天和适应性免疫反应，往往不能清除细菌，导致目标组织的持续感染和疾病。先天免疫细胞上toll样受体2对Bb脂蛋白的早期识别似乎对宿主组织中的细菌清除至关重要，然而我们目前对预防莱姆病的特定先天反应还没有明确的了解。我们之前的研究表明，IL-10缺陷小鼠（IL-10-/-）对宿主组织中Bb水平的控制明显优于野生型小鼠（WT），从而使IL-10成为唯一能显著影响Bb清除的细胞因子。我们的初步数据进一步表明，1)活的（而不是杀死的）Bb引起小鼠巨噬细胞（MX）和树突状细胞（dc）的高IL-10水平，2)分泌的IL-10水平可以显著抑制随后的常驻MX激活，3)感染后24小时内小鼠皮肤中检测到显著的IL-10水平，4)IL-10-/-小鼠不表现出这些抑制作用，导致MX活性增强和免疫清除。我们假设IL-10在对Bb感染的反应中，抑制宿主先天免疫反应，这对宿主组织有效清除Bb至关重要，并且MX和DC功能是这种失调的宿主反应的核心。本提案的总体目标是：1)确定在小鼠组织中最初检测并响应Bb的细胞类型，2)确定在感染过程中哪些细胞类型负责产生IL-10，以及3)描述哪些免疫细胞类型受到Bb引发的IL-10的不利影响以及哪些免疫机制失调。为了实现这些目标，Aim 1将比较IL-10对mx和dc摄取、内部运输和体外介导Bb杀伤能力的影响，包括激活/成熟标记物的表达。Aim 2将利用一些基因突变的小鼠品系来描述造血细胞和非造血细胞，以及mx、dc和T细胞在体内Bb感染期间产生IL-10和/或对IL-10产生反应的相对重要性。目的3将严格测试IL-10受体阻断抗体是否可用于治疗感染Bb的小鼠。这些研究将阐明在莱姆病发展过程中被抑制的特定宿主免疫机制，从而开发新的治疗方法。伯氏疏螺旋体感染导致宿主组织显著增加IL-10的产生，从而抑制宿主的免疫反应，阻碍其清除这种感染的能力，从而导致莱姆病的发展。IL-10是目前已知唯一显著影响莱姆病发展的细胞因子，是了解莱姆病免疫逃逸机制的重要线索。这些研究旨在鉴定产生IL-10的宿主细胞，以及被IL-10失调的免疫细胞，从而确定可能靶向治疗莱姆病患者的机制。